Sonographic Detection of Prophylactic Pancreatic Stents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-01

Study Completion Date

2020-04-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Retention of pancreatic stents for prophylaxis of post-ERCP pancreatitis (PEP) is assessed by abdominal x-ray according to international Guidelines. The current study aimed to analyze whether prophylactic pancreatic stents can be detected by transdermal ultrasound to save the x-ray examination.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal

NCT04546867

Post-ERCP Acute Pancreatitis Pancreatic Stent Ultrasound +1 more

COMPLETED NA

Diagnostic and Interventional Therapy in Acute Pancreatitis

NCT00699933

Acute Pancreatitis

UNKNOWN

Endoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis

NCT07093996

Acute Pancreatitis (AP)

NOT_YET_RECRUITING NA

Early Pancreatic Duct Stent Removal in Preventing Post-endoscopic Pancreatitis

NCT01449084

Acute Pancreatitis

COMPLETED NA

Incidence, Risk Factors and Endoscopic Retrieval of Proximally Migrated Pancreatic Stents

NCT05431517

Pancreatic Stenting Pancreatic Stent Displacement

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP). Several pharmacologic and procedure-related measurements have been established for post-ERCP pancreatitis (PEP) prophylaxis one being the placement of pancreatic duct stents in patients with high risk for PEP. The beneficial role of pancreatic stenting in the prophylaxis of PEP was demonstrated in large meta-analyses. The used stents have a high potential of self dislodgment, retained stents have to be removed endoscopically after 5-10 days. For evaluation of spontaneous stent passage abdominal x-ray ist used and accordingly retained stents removed. The current study aimed to analyze whether prophylactic pancreatic stents can be detected by transdermal ultrasound to save the x-ray examination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatitis Stent Dislodgement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with pancreatic stent

abdominal ultrasound and x-ray for stent detection.

Group Type EXPERIMENTAL

Abdominal ultrasound

Intervention Type DIAGNOSTIC_TEST

Abdominal ultrasound for detection of the pancreatic stent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abdominal ultrasound

Abdominal ultrasound for detection of the pancreatic stent

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient after pancreatic stent placement for prophylaxis of post-ERCP pancreatitis
* age 18-79
* signed informed consent

Exclusion Criteria

* any disease that rules out study participation
* patient not legally competent to sign informed consent
* chronic pancreatis as indication for pancreatic stenting

Minimum Eligible Age

18 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No